MedTrace Logo

Role of Minocycline in First Episode Psychosis

NCT00916461 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2009-06-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether the addition of minocycline or placebo to treatment as usual (TAU):

1. prevents the accumulation of negative symptoms and intellectual decline following a first episode of non-affective psychosis; and
2. whether minocycline stabilizes the efficacy of antipsychotics.

Conditions

  • First Episode Psychosis

Interventions

DRUG

Minocycline

Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.

DRUG

Placebo

Placebo + treatment as usual.

Sponsors & Collaborators

  • Rawalpindi Medical College, Pakistan

    collaborator OTHER

  • Pakistan Institute of Living and Learning

    collaborator OTHER

  • University of Sao Paulo

    collaborator OTHER

  • Stanley Medical Research Institute

    lead OTHER

Principal Investigators

  • Imran B Chaudhry, MD · University of Manchester

  • Jaime EC Hallak, MD · University of San Paulo, Brazil

  • Nusrat Husain, MD · University of Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Brazil
  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916461 on ClinicalTrials.gov